HER4 Mediates Ligand-Dependent Antiproliferative and Differentiation Responses in Human Breast Cancer Cells
- 1 July 2001
- journal article
- research article
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 21 (13) , 4265-4275
- https://doi.org/10.1128/mcb.21.13.4265-4275.2001
Abstract
The function of the epidermal growth factor receptor (EGFR) family member HER4 remains unclear because its activating ligand, heregulin, results in either proliferation or differentiation. This variable response may stem from the range of signals generated by HER4 homodimers versus heterodimeric complexes with other EGFR family members. The ratio of homo- and heterodimeric complexes may be influenced both by a cell9s EGFR family member expression profile and by the ligand or even ligand isoform used. To define the role of HER4 in mediating antiproliferative and differentiation responses, human breast cancer cell lines were screened for responses to heregulin. Only cells that expressed HER4 exhibited heregulin-dependent antiproliferative responses. In-depth studies of one line, SUM44, demonstrated that the antiproliferative and differentiation responses correlated with HER4 activation and were abolished by stable expression of a kinase-inactive HER4. HB-EGF, a HER4-specific ligand in this EGFR-negative cell line, also induced an antiproliferative response. Moreover, introduction and stable expression of HER4 in HER4-negative SUM102 cells resulted in the acquisition of a heregulin-dependent antiproliferative response, associated with increases in markers of differentiation. The role of HER2 in these heregulin-dependent responses was examined through elimination of cell surface HER2 signaling by stable expression of a single-chain anti-HER2 antibody that sequestered HER2 in the endoplasmic reticulum. In the cell lines with either endogenously (SUM44) or exogenously (SUM102) expressed HER4, elimination of HER2 did not alter HER4-dependent decreases in cell growth. These results suggest that HER4 is both necessary and sufficient to trigger an antiproliferative response in human breast cancer cells.Keywords
This publication has 58 references indexed in Scilit:
- Defects in pathfinding by cranial neural crest cells in mice lacking the neuregulin receptor ErbB4Nature Cell Biology, 2000
- Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinaseOncogene, 1999
- Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinaseOncogene, 1999
- Epidermal Growth Factor Receptor Family and ChemosensitizationJNCI Journal of the National Cancer Institute, 1997
- Evaluation of HER-2 neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: A case-control studyInternational Journal of Radiation Oncology*Biology*Physics, 1996
- Epidermal Growth Factor-related Peptides Activate Distinct Subsets of ErbB Receptors and Differ in Their Biological ActivitiesJournal of Biological Chemistry, 1996
- Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer researchBreast Cancer Research and Treatment, 1995
- Neu differentiation factor: A transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unitCell, 1992
- Isolation of the NeuHER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cellsCell, 1992
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987